In today’s business climate, medical device and life sciences companies need to be properly positioned at each phase of development with the appropriate plans in place for later portfolio development stages. Panelists will review key business and intellectual property management tools and strategies that are needed at the early-, mid- and late-growth stages as well the types of funding needed to fuel growth throughout the product life cycle. We also will address how and when you should plan for an IPO as well as other exit strategies, including merger and acquisitions.
Topics include:
- How companies can balance the need to continually innovate while minimizing the failure rate
- How to realize revenue streams earlier in the process
- How to evaluate innovation based on potential business value
Panelists:
- Keith Lindenbaum, Partner, Foley & Lardner LLP
- David Kantaros, Partner, Foley & Lardner LLP
- Fouad Azzam, Ph.D., General Partner, Life Sciences Partners
- Jeff Barlow, Managing Director, Head of US Life Sciences Investment Banking, Canaccord Adams
- Stacy Coen, Senior Director of Business Development, Genzyme Corporation
- Robert Mashal, Ph.D., President & CEO, NKT Therapeutics Inc.
Related Insights
July 25, 2025
Foley Viewpoints
Thorny Laws That ICHRA Vendors Should Consider, Part Three: FinTech Edition
We continue our series on the legal and regulatory challenges facing individual coverage health reimbursement arrangements (ICHRAs); this…
July 24, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…